Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant

Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.


An pundit prediction panel recommended on Tuesday that Contrave, a unusual weight-loss medication that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 opt in favor of Contrave came into the middle action concerns that the dope might moot blood pressure in some patients and further the risk of heart attacks and strokes in the midst some users, according to the Associated Press stallion xl reviews. But panelists voted 11-8 earlier in the lifetime that those budding health risks could be studied after Contrave was approved.



The FDA does not have to follow the counsel of its advisory committees, but it typically does. The intermediation is expected to become a decision on Contrave by Jan 31, 2011, the wire assistance reported. contrave is manufactured by orexigen therapeutics inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of shelter concerns, according to the AP Irritable colon symptoms. Last July, a enquiry funded by Orexigen and published in The Lancet found that Contrave helped users surge pounds when infatuated along with a in the pink intake and exercise.



People who took the pharmaceutical for more than a year irrecoverable an middling of 5 percent or more of body weight, depending on the dispense used, the team said. However, the regimen did come with opinion effects, and about half of swotting participants dropped out before completing a year of treatment. Contrave is alliance of two established drugs, naltrexone (Revia, used to pugnacity addictions) and the antidepressant bupropion (known by a thousand of names, including Wellbutrin).



The drug appears to push up weight loss by changing the workings of the body's median nervous system, the researchers said. The weigh enrolled men (15 percent) and women (85 percent) from around the country, ranging in life-span from 18 to 65. They were all either paunchy or overweightm, with considerable blood overfed levels or high blood pressure.